Matthias Steiert
Los Gatos Pharmaceuticals, USA
Title: LPG-1, a novel anti-tumor prodrug-conjugate nanoparticle formulation overcoming severe side effects of existing treatment
Biography
Biography: Matthias Steiert
Abstract
A novel proprietary product is under development that overcomes existing challenges based on the compound SN-38 and its parent compounds Topotecan and Irinotecan. It overcomes the short tumor half-life (Topotecan and Irinotecan) and enterohepatic/GI toxicitiy (SN-38). A chemical modification of SN-38 resulting in a product that will be metabolized into the active compound combined with a nanoparticle formulation using PLGA and other block-copolymers has demonstrated improved efficacy in vitro and in vivo as compared to parent camptothecins. Increased tumor concentrations and duration of exposure as compared to native SN-38 should, therefore, be achievable via passive targeting resulting in potentially improved safety profile by reducing entero-hepatic recirculation. Target indication chemotherapy of solid tumors of this product is colorectal cancer, NSCLC, and others.